XML 61 R27.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue Recognition (Tables)
 12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Timing of Revenue Recognition
The following table illustrates the timing of the Company’s revenue recognition patterns:
Year Ended December 31,
202420232022
Software products and services – point in time51.4 %49.1 %47.3 %
Software products and services – over time35.5 24.3 27.6 
Drug Discovery – point in time6.8 12.7 8.8 
Drug Discovery – over time6.3 13.9 16.3 
Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue
The following table presents the revenue recognized from the sources of software products and services revenue:
 
Year Ended December 31,
 202420232022
On-premise software$104,020 $104,511 $84,487 
Hosted software35,253 20,381 14,890 
Software maintenance23,279 23,066 19,996 
Professional services9,797 9,366 15,205 
Revenue from contracts with customers172,349 157,324 134,578 
Software contribution8,016 1,800 1,000 
Total software revenue$180,365 $159,124 $135,578 
The following table presents the revenue recognized from the sources of drug discovery revenue:
 
Year Ended December 31,
 202420232022
Drug discovery services revenue from contracts with customers$25,143 $54,720 $43,427 
Drug discovery contribution2,031 2,822 1,950 
Total drug discovery revenue$27,174 $57,542 $45,377 
Schedule of Contract Balances
Contract balances were as follows:
 
As of
December 31,
2024
As of
December 31,
2023
Contract assets$16,564 $21,107 
Deferred revenue, short-term:  
Software products and services75,660 44,218 
Drug discovery36,284 12,013 
Deferred revenue, long-term:  
Software products and services14,393 2,407 
Drug discovery94,421 6,636